Health Catalyst (NASDAQ:HCAT - Get Free Report) will be issuing its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of $0.10 per share for the quarter. Health Catalyst has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Investors that are interested in participating in the company's conference call can do so using this link.
Health Catalyst (NASDAQ:HCAT - Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported $0.12 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.04. The firm had revenue of $75.90 million for the quarter, compared to the consensus estimate of $74.96 million. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The company's revenue was up 3.7% on a year-over-year basis. During the same period last year, the firm posted ($0.21) EPS. On average, analysts expect Health Catalyst to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Health Catalyst Stock Up 1.6 %
NASDAQ:HCAT traded up $0.13 during mid-day trading on Wednesday, reaching $8.04. 327,826 shares of the stock were exchanged, compared to its average volume of 562,383. The stock has a market capitalization of $486.18 million, a P/E ratio of -4.28 and a beta of 1.32. The company has a 50 day simple moving average of $7.91 and a 200-day simple moving average of $7.02. Health Catalyst has a 1 year low of $5.42 and a 1 year high of $11.41.
Wall Street Analyst Weigh In
HCAT has been the topic of several research analyst reports. Piper Sandler lowered their price target on Health Catalyst from $14.00 to $11.00 and set an "overweight" rating on the stock in a report on Monday, August 26th. JPMorgan Chase & Co. lifted their price target on shares of Health Catalyst from $10.00 to $13.00 and gave the company an "overweight" rating in a research report on Wednesday, September 4th. Cantor Fitzgerald reissued an "overweight" rating and issued a $16.00 price objective on shares of Health Catalyst in a research report on Friday, October 4th. Evercore ISI increased their target price on Health Catalyst from $8.00 to $10.00 and gave the company an "outperform" rating in a research note on Tuesday, October 8th. Finally, Stephens cut their price objective on shares of Health Catalyst from $8.00 to $7.00 and set an "equal weight" rating on the stock in a report on Thursday, August 8th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, Health Catalyst currently has a consensus rating of "Moderate Buy" and a consensus price target of $11.58.
Get Our Latest Stock Analysis on HCAT
Insider Activity
In related news, COO Daniel Lesueur sold 8,137 shares of the company's stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the sale, the chief operating officer now directly owns 140,108 shares of the company's stock, valued at approximately $1,062,018.64. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, COO Daniel Lesueur sold 8,137 shares of the stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the completion of the transaction, the chief operating officer now directly owns 140,108 shares of the company's stock, valued at approximately $1,062,018.64. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the company's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the sale, the insider now owns 255,881 shares in the company, valued at $1,847,460.82. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 35,396 shares of company stock valued at $258,415. Insiders own 2.70% of the company's stock.
About Health Catalyst
(
Get Free Report)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
See Also
Before you consider Health Catalyst, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Health Catalyst wasn't on the list.
While Health Catalyst currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
